Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians.
Level 5 - mechanism / opinion, no new human data
Narrative review of pharmacological mechanisms and measurement techniques without systematic methodology.
PubMed 11191730 · doi:10.1592/phco.21.1.11.34439
What was done
This narrative review synthesized literature on the intracellular anabolic phosphorylation pathways, measurement methodologies, and clinical pharmacology of nucleoside analog reverse transcriptase inhibitors (zidovudine, didanosine, zalcitabine, stavudine, abacavir, and lamivudine).
What was found
The abstract reports no quantitative data or specific numerical results. It qualitatively describes that nucleoside analogs undergo intracellular phosphorylation to active triphosphates that competitively inhibit HIV reverse transcriptase. Both intracellular and extracellular factors influence this activation, and study results remain difficult to compare across studies due to non-standardized and complex analytical methods.
Why it matters
Understanding the intracellular kinetics of nucleoside analog activation helps explain therapeutic response, toxicities, and optimal dosing regimens in antiretroviral therapy.
Limits
The abstract describes a narrative review with no primary clinical trial data, quantitative metrics, or systematic search strategy. High methodological variability and lack of standardized assay protocols across cited studies limit direct cross-study comparisons.
Cited by
- supports The HIV drug AZT is a nucleoside analog that enters cells and is intracellularly converted into an active nucleotide to inhibit viral replication.